Company Overview and News

S&P/ASX 200 rallies to close up 0.2%, March VIX futures still above 19

S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) rallied from its low around 1.00pm to finish up for the day.

S&P/ASX 200 recovers losses to finish slightly up, A2M up 29%

Gains in the Consumer Staples sector, +3.38%, more than offset losses in the Materials sector, -2.25%.

S&P/ASX 200 breaks into positive territory in the afternoon, A2M up 26%

S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) has recovered early losses to be trading up for the day with an hour to go.

a2 Milk Company signs deal with Fonterra, net profit surges 150%

a2 Milk Company Ltd (Australia) (ASX:A2M) has signed a joint marketing deal with dairy giant Fonterra Co-operative Group (NZE:FCG) focused on its a2 Milk®.

S&P/ASX 200 recovers morning losses to be flat around midday, A2M up 25%

S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) has recovered 25 points from its morning low to be flat just after midday.

S&P/ASX 200 opens lower as expected but begins to bounce, BHP down near 5%

The ASX 200 is down 8 points or 0.2% to 5,933 just after opening bell this morning.

S&P/ASX 200 set to open lower after Dow Jones goes down 1%

Furthermore, BHP Billiton Limited (ASX:BHP) is set to drag the Australian market down today after failing to impress investors with its result yesterday after-market.

A2 Milk expands into North East region of the US, targeting 5000 stores by January

A2 Milk Company Ltd (ASX:A2M) is expanding its position in the US as it targets the north-east region, having achieved sustainable levels of sales in California, the south-east region and natural retail chains.

Lithium producer to join S&P/ASX All Australian 200 Index

Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.

China Market Developments


Investor presentation Sydney


Investor presentation Sydney


Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...